GlassScriptPhysician profile
Alam N Khan
NPI 1629047162
$89,219.39
in general payments reported to CMS, 2019-2025
62 companies · $7,625 in 2025
The $7,625 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $1,318 · 2021: $24K · 2022: $15K · 2023: $27K · 2024: $13K · 2025: $7,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $7,529 · Education: $549 · Travel and Lodging: $39.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,368.75 |
| Food and Beverage | $7,528.84 |
| Education | $548.95 |
| Travel and Lodging | $39.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $49,746.66 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $24,573.42 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $5,054.83 | 2022 | |
| Livanova USA, INC. | $1,050.82 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $737.57 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $652.57 | 2019-2025 | Ultomiris, Soliris |
| Ucb, INC. | $608.47 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Mdd US Operations, LLC | $605.30 | 2019-2025 | Gocovri, Gocovri |
| Celgene Corporation | $545.73 | 2022-2025 | Zeposia |
| Pfizer INC. | $485.80 | 2023-2025 | |
| Lilly USA, LLC | $398.63 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Emd Serono, INC. | $392.69 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $350.50 | 2019-2025 | Austedo Xr, Ajovy |
| Biogen, INC. | $336.41 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Argenx US, INC. | $303.78 | 2022-2025 | Vyvgart |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $243.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $241.55 | 2021-2022 | |
| Allergan, INC. | $201.95 | 2019-2021 | |
| Neurelis, INC. | $200.62 | 2023-2024 | Valtoco |
| Csl Behring | $189.24 | 2019-2025 | Hizentra |
| Genentech USA, INC. | $160.83 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Sunovion Pharmaceuticals INC. | $139.96 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $133.77 | 2022-2023 | Trudhesa |
| Lundbeck LLC | $127.88 | 2023-2025 | Vyepti, Rexulti |
| Vanda Pharmaceuticals INC. | $118.29 | 2025 | Ponvory |
| Acadia Pharmaceuticals INC | $117.97 | 2019-2025 | Nuplazid, Daybue |
| Supernus Pharmaceuticals, INC. | $113.39 | 2021-2022 | |
| Amgen INC. | $100.02 | 2019-2024 | Uplizna |
| Acorda Therapeutics, INC | $92.05 | 2019-2024 | Ampyra, Inbrija |
| Amneal Pharmaceuticals LLC | $86.69 | 2019-2024 | Rytary, Lyvispah |
| Ipsen Biopharmaceuticals, INC | $83.53 | 2024-2025 | Dysport |
| Alnylam Pharmaceuticals INC. | $74.53 | 2019-2024 | Onpattro, Givlaari |
| Mallinckrodt Hospital Products INC. | $71.23 | 2022-2024 | Acthar |
| Neurocrine Biosciences, INC. | $67.76 | 2019-2023 | Ongentys, Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $66.24 | 2024-2025 | Hyqvia |
| Sk Life Science, INC. | $55.09 | 2022 | |
| Merz Pharmaceuticals, LLC | $52.76 | 2022-2024 | Xeomin |
| Jazz Pharmaceuticals INC. | $50.62 | 2024-2025 | |
| Corium, LLC | $48.93 | 2023 | Adlarity |
| Janssen Biotech, INC. | $45.26 | 2025 | |
| Mallinckrodt Enterprises LLC | $44.12 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $43.91 | 2023-2024 | Fycompa |
| Aucta Pharmaceuticals, INC. | $43.30 | 2024-2025 | Motpoly Xr |
| Tg Therapeutics, INC. | $37.02 | 2024-2025 | |
| Akcea Therapeutics, INC. | $29.06 | 2019 | |
| Promius Pharma LLC | $25.63 | 2019 | |
| Abbott Laboratories | $23.44 | 2024 | Amplatzer Talisman |
| Sumitomo Pharma America, INC. | $21.74 | 2023 | Aptiom |
| Globus Medical, INC. | $21.43 | 2025 | Senza |
| Ge Healthcare | $18.86 | 2020 | |
| Axsome Therapeutics, INC. | $18.82 | 2023 | Sunosi |
| Genzyme Corporation | $18.77 | 2019 | |
| Tanabe Pharma America, INC. | $17.45 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $15.69 | 2023 | Rexulti |
| Grifols USA, LLC | $15.61 | 2025 | Gamunex-C |
| Upsher-Smith Laboratories LLC | $15.48 | 2022 | |
| Averitas Pharma INC. | $15.29 | 2023 | Qutenza |
| Sanofi-Aventis U.S. LLC | $14.62 | 2020 | |
| Medtronic USA, INC. | $13.70 | 2020 | |
| Medtronic Vascular, INC. | $13.56 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.15 | 2023 | Keveyis |
| Strongbridge US INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alam Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.